Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer

659 Pages·2010·6.55 MB·English

by  Raymond M. Reilly

MONOCLONAL ANTIBODY
AND PEPTIDE-TARGETED
RADIOTHERAPY OF
CANCER
Editedby
Raymond M. Reilly

MONOCLONAL ANTIBODY
AND PEPTIDE-TARGETED
RADIOTHERAPY OF
CANCER

MONOCLONAL ANTIBODY
AND PEPTIDE-TARGETED
RADIOTHERAPY OF
CANCER
Editedby
Raymond M. Reilly
Copyright(cid:2)2010byJohnWiley&Sons,Inc.Allrightsreserved.
PublishedbyJohnWiley&Sons,Inc.,Hoboken,NewJersey
PublishedsimultaneouslyinCanada
Nopartofthispublicationmaybereproduced,storedinaretrievalsystem,ortransmittedinanyformorby
anymeans,electronic,mechanical,photocopying,recording,scanning,orotherwise,exceptaspermitted
underSection107or108ofthe1976UnitedStatesCopyrightAct,withouteitherthepriorwritten
permissionofthePublisher,orauthorizationthroughpaymentoftheappropriateper-copyfeetothe
CopyrightClearanceCenter,Inc.,222RosewoodDrive,Danvers,MA01923,[phone],fax(978)
750-4470,oronthewebatwww.copyright.com.RequeststothePublisherforpermissionshouldbe
addressedtothePermissionsDepartment,JohnWiley&Sons,Inc.,111RiverStreet,Hoboken,NJ07030,
[phone],fax[phone],oronlineathttp://www.wiley.com/go/permission.
LimitofLiability/DisclaimerofWarranty:Whilethepublisherandauthorhaveusedtheirbestefforts
inpreparingthisbook,theymakenorepresentationsorwarrantieswithrespecttotheaccuracyor
completenessofthecontentsofthisbookandspecificallydisclaimanyimpliedwarrantiesof
merchantabilityorfitnessforaparticularpurpose.Nowarrantymaybecreatedorextendedbysales
representativesorwrittensalesmaterials.Theadviceandstrategiescontainedhereinmaynotbesuitable
foryoursituation.Youshouldconsultwithaprofessionalwhereappropriate.Neitherthepublishernor
authorshallbeliableforanylossofprofitoranyothercommercialdamages,includingbutnotlimitedto
special,incidental,consequential,orotherdamages.
Forgeneralinformationonourotherproductsandservicesorfortechnicalsupport,pleasecontactour
CustomerCareDepartmentwithintheUnitedStatesat(800)762-2974,outsidetheUnitedStatesat(317)
572-3993orfax(317)572-4002.
Wileyalsopublishesitsbooksinavarietyofelectronicformats.Somecontentthatappearsinprintmay
notbeavailableinelectronicformats.FormoreinformationaboutWileyproducts,visitourwebsiteat
www.wiley.com.
LibraryofCongressCataloging-in-PublicationData:
Monoclonalantibodyandpeptide-targetedradiotherapyofcancer/editedby
RaymondM.Reilly.
p.;cm.
Includesbibliographicalreferencesandindex.
ISBN978-0-470-24372-5(cloth)
1. Cancer–Radioimmunotherapy. 2. Monoclonalantibodies–Therapeuticuse.
3. Tumorproteins. I. Reilly,Raymond.
[DNLM: 1. Neoplasms–radiotherapy. 2. Antibodies,Monoclonal–therapeutic
use. 3. Peptides–therapeuticuse. 4. Radioimmunotherapy–methods. 5. Receptors,
Peptide–therapeuticuse. QZ269M7512010]
RC271.R26M662010
616.99040642–dc22 2009045879
PrintedinSingapore
10 9 8 7 6 5 4 3 2 1
Tomymother,whoalwaysusedtoaskme,“Whatisamonoclonalantibody?”
and,inanotherlifewouldhavebeenawonderfulscientistwith
herinbornfascinationwithmedicaldiscoveryandknowledge.

CONTENTS
Preface xvii
Contributors xxi
1. AntibodyEngineering:OptimizingtheDeliveryVehicle 1
DianeE.Milenic
1.1 Introduction 1
1.2 Intact Murine Monoclonal Antibodies 2
1.3 Recombinant ImmunoglobulinMolecules 4
1.3.1 Chimeric Monoclonal Antibodies 5
1.3.2 Humanized MonoclonalAntibodies 6
1.3.3 Human MonoclonalAntibodies 9
1.4 Nanobodies 10
1.5 Domain-Deleted Monoclonal Antibodies 12
1.6 Hypervariable Domain RegionPeptides 13
1.7 Fv Fragments 14
1.7.1 Multimeric FvForms 16
1.8 Minibodies 19
1.9 SelectiveHighAffinity Ligands 21
1.10 Affibodies 21
1.11 Other Strategies 23
1.11.1 Fc Domain and the Neonatal FcReceptor 23
1.11.2 PEGylation 25
1.11.3 AlbuminBinding 26
1.12 Concluding Remarks 28
References 28
2. TheRadiochemistryofMonoclonalAntibodiesandPeptides 39
RaymondM.Reilly
2.1 Introduction 39
2.2 Tumor and Normal Tissue Uptake ofMonoclonal
Antibodies andPeptides 40
2.3 Selection of aRadionuclide for Tumor Imaging 41
2.4 Selection of aRadionuclide for TargetedRadiotherapy 44
vii